Gilead's CAR-T cell therapy shows promise in deadly brain cancer\n\nPublished on 06/01/2025 at 08:01\n\nShare\nThis article is reserved for\nUnlock the article: REGISTER NOW!\nAlready a customer?\n\n© Reuters - 2025\n\n###\n\nGilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%). Employees 17,600 Sector Calendar 09:12am\n\n###\n\nTrading Rating\nInvestor Rating\nESG MSCI AAA\nSell Buy\nMean consensus OUTPERFORM\nNumber of Analysts\nLast Close Price 110.08 USD\nAverage target price 115.04 USD\nSpread / Average Target +4.50% \n\nQuarterly revenue - Rate of surprise 5.\n\nGilead's CAR-T cell therapy shows promise in deadly brain cancer\n\nBest financial portal\n+951% of historical performance\nMore than 20 years at your side\n+ 1,000,000 members\nQuick & easy cancellation\nOur Experts are here for you\nOUR EXPERTS ARE HERE FOR YOU\nMonday - Friday 9am-12pm / 2pm-6pm GMT + 1\nContact us\nLegal information | Cookie settings | MarketScreener Blog || Copyright © 2025 Surperformance SAS. All rights reserved.

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Gilead Sciences, Inc. has announced that its CAR-T cell therapy shows promise in treating deadly brain cancer, highlighting advancements in oncology research.